The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Takeda’s CMV Drug Maribavir Gets FDA’s Priority Review
Takeda Pharmaceutical said on May 21 that the US FDA granted a priority review status for its new drug application for maribavir for the treatment of certain patients infected with cytomegalovirus (CMV) post-transplant. The priority status was granted for use…
To read the full story
Related Article
- Takeda Files CMV Drug Maribavir in Japan
November 20, 2023
- Takeda’s CMV Drug Livtencity Bags US Approval
November 25, 2021
- Takeda’s CMV Drug Maribavir Earns FDA AdCom Backing
October 11, 2021
- Maribavir Hits Primary Goal for Post-Transplant CMV Infection: Takeda
December 8, 2020
BUSINESS
- Oncolys Aims for First-Line Use of Telomelysin in Esophageal Cancer
January 19, 2026
- 3D Plans to Lift Toho Stake to Up to 27%
January 19, 2026
- Nobelpharma Launches Pediatric Sleep Aid Melatonin in China
January 19, 2026
- iPark Institute to Launch AI-Based Platform to Link Investors with Startups
January 16, 2026
- Acromegaly Drug Palsonify Meets Primary Endpoint in Japan PII/PIII Trial
January 16, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…